MYST Family KAT Inhibitor Compounds for Selective Enzyme Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new inhibitors of the MYST family of Lysine Acetyl Transferases (KATs) to address their role in diseases such as cancer, as existing inhibitors are limited in efficacy and specificity.
Innovation Solution
Development of compounds that inhibit the activity of KATs of the MYST family, including TIP60, KAT6B, MOZ, HBO1, and MOF, through specific chemical structures that target these enzymes, potentially enhancing cancer treatment by inhibiting their activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing inhibitors of MYST family KATs are used, then some inhibitory activity is achieved, but efficacy and specificity are limited
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific structural features targeted at particular MYST family members. Each inhibitor compound is tailored with specific molecular characteristics that enable selective binding to particular KAT enzymes (e.g., MOZ, HBO1, TIP60, MOF), thereby achieving both high efficacy and specificity simultaneously rather than using a one-size-fits-all approach
Solution Approach 2:
The patent utilizes parameter changes by systematically varying chemical parameters of the inhibitor molecules, such as molecular weight, functional groups, and structural configurations. This allows optimization of binding affinity and selectivity for different MYST family members, transforming the inhibitory activity into a controlled and可调 parameter that can be precisely tuned for specific therapeutic applications
2Reliability
If MYST family KATs are inhibited, then cancer treatment benefits are achieved, but the complexity of targeting specific family members increases
Solution Approach 1:
The patent applies segmentation by dividing the MYST family KATs into distinct target groups and developing separate inhibitor compounds for each member (MOZ, HBO1, TIP60, MOF). This modular approach allows independent optimization of each inhibitor while maintaining overall therapeutic effectiveness, reducing the complexity of achieving selective targeting compared to attempting to inhibit all family members simultaneously with a single agent
Solution Approach 2:
The patent applies universality by creating a series of inhibitor compounds that can target multiple MYST family members through shared structural motifs, while also providing member-specific inhibitors for critical targets. This multi-functional approach allows a single research program to address the entire MYST family without requiring entirely separate development pathways for each member, thereby managing complexity while maintaining comprehensive therapeutic coverage
Data Source
AI summary
A compound of formula (I), or a pharmaceutical salt thereof: